Sanofi (SNY)
| Market Cap | 116.88B |
| Revenue (ttm) | 48.82B |
| Net Income (ttm) | 6.81B |
| Shares Out | 1.23B |
| EPS (ttm) | 5.45 |
| PE Ratio | 8.78 |
| Forward PE | 10.34 |
| Dividend | $2.21 (4.62%) |
| Ex-Dividend Date | May 9, 2025 |
| Volume | 5,607,129 |
| Open | 48.07 |
| Previous Close | 47.62 |
| Day's Range | 47.45 - 48.11 |
| 52-Week Range | 45.80 - 60.12 |
| Beta | 0.41 |
| Analysts | Buy |
| Price Target | 62.50 (+30.59%) |
| Earnings Date | Jul 24, 2025 |
About SNY
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; inf... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for SNY stock is "Buy." The 12-month stock price forecast is $62.5, which is an increase of 30.59% from the latest price.
News
BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Bluep...
Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease
The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the elderly and is characterized by itchiness, blisters and lesions.
Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval based on pivotal results showing improvements in sustained disease remission and reductions...
RFK Jr weighs review of vaccines citing aluminum use, Bloomberg News reports
U.S. Health Secretary Robert F. Kennedy Jr. is considering asking a key government vaccine advisory panel to examine vaccines that contain aluminum ingredients, Bloomberg News reported on Wednesday, c...
RFK Jr.'s new vaccine advisors will vote on flu shots containing mercury
A revamped government panel of vaccine advisors appointed by Health and Human Services Secretary Robert F. Kennedy Jr. will soon vote on a shot preservative that contains mercury, which is safely used...
Press release: Sanofi successfully prices €1.5 billion bond issue
Sanofi successfully prices €1.5 billion bond issue Paris, June 17, 2025 - Sanofi announces that it has successfully priced its offering of €1.5 billion of notes across 2 tranches: €750 million fixed-...
SNY Investors Have Opportunity to Join Sanofi Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $SNY--SNY Investors Have Opportunity to Join Sanofi Fraud Investigation with the Schall Law Firm.
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respirator...
Sanofi (SNY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Sanofi (NASDAQ:SNY) Goldman Sachs 46th Annual Global Healthcare Conference Call June 10, 2025 4:00 PM ET Company Participants Brian Foard - Executive VP & Head of Specialty Care Conference Call Parti...
Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.
Investors will be waiting for news on how the makeup of a reconstituted ACIP will look like.
Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan
Sanofi Launches 2025 Global Employee Stock Purchase Plan Paris, June 5, 2025. Sanofi's global employee shareholder plan, Action 2025, opens on June 10, 2025, to around 70,000 employees in 55 countries...
Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector
ASCO: new Sarclisa data support subcutaneous administration with on-body injector New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational on-bo...
Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz
Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals and how to trade in the sector.
Johnson Fistel Investigates Fairness of Proposed Sale of Blueprint Medicines
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP has launched an investigation into whether the board members of Blueprint Medicines Corporation (NASDAQ: BPMC) breached their fiduciar...
Sanofi-Blueprint deal is a bullish signal about biotech M&A
The American Society of Clinical Oncology (ASCO) is kicking off its annual meeting in Chicago this week, with all eyes on the latest developments and acquisition deals in the pharmaceutical space. San...
Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor for Inflammatory Diseases and Achievement of Significant Milestone Under Collaboration with Sanofi
--Completion of GLP toxicology studies associated with a $50 million payment to Recludix under the collaboration with Sanofi
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio PARIS and CAMBRIDGE, Mass. , June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medi...
Sanofi buys US biopharma group Blueprint in $9.1 bln deal
French pharma group Sanofi has agreed to buy US-based Blueprint Medicines Corporation , a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, the companies s...
Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion
The deal includes a drug approved in the U.S. and the EU for systemic mastocytosis, a rare immunology disease, as well as an early-stage immunology pipeline, the companies said.
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Sanofi: Finding Value In The Wake Of Itepekimab's Disappointment
Sanofi faces setbacks after itepekimab's Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on Dupixent. Despite challenges, Sanofi is attractively valued, with my DCF anal...
Itepekimab Failure A Setback For Sanofi And Regeneron
Itepekimab's inconsistent phase 3 results represent a setback for Regeneron Pharmaceuticals and Sanofi. The results do not support regulatory submissions and a 3-4 year approval delay, and lower peak ...
Sanofi, Regeneron's Itepekimab Delivers Mixed Results in Late-Stage Trials
Sanofi and Regeneron said that drug candidate Itepekimab didn't meet primary endpoint in a phase three study, although a benefit was seen earlier in the trial.
Press Release: Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs
Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs
US FDA approves use of Sanofi's meningococcal vaccine in infants
French drugmaker Sanofi said the U.S. Food and Drug Administration has approved its meningococcal vaccine for use in infants as young as six weeks, making it the first shot intended for the age group.